, Tracking Stock Market Picks
Enter Symbol:
Rating: BABY
Buy $50

Natus Medical Incorporated (NASDAQ: BABY) reiterated to Buy with price target $50 by Roth Capital

Tuesday,  Jan 12, 2016  8:25 AM ET by Lynn Gilbert

Roth Capital reiterated Natus Medical Incorporated (NASDAQ: BABY) to Buy with price target
$50. Previously, Roth Capital rated Natus Medical Incorporated (NASDAQ: BABY) to Buy with price target $42 on 01/12/2015, when the stock price was valued at $37.74.

Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy